Related Experiment Videos
Priorities, Expectations, Perceptions of Time in Tight Range and Support Needs Relating to Closed-Loop Therapy Among
Alexandros L Liarakos1,2, Iskandar Idris1,2, Emma G Wilmot1,2
1Department of Diabetes and Endocrinology, University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, UK.
Aims:
To assess factors influencing closed-loop system choice, perceptions of treatment satisfaction and glycaemic targets, perceived benefits and expectations of therapy, and support needs among adults with Type 1 diabetes (T1D) using, awaiting initiation of or considering closed-loop therapy.
Materials And Methods:
SELECT HCL was a cross-sectional survey study conducted at a specialist secondary care diabetes service between September 2025 and February 2026. Adults with T1D completed an anonymous online questionnaire assessing experiences and perspectives relating to closed-loop therapy. Descriptive, subgroup, and multivariable logistic regression analyses were performed.
Results:
Overall, 166 participants were included (median age 47 years; HbA1c 52 mmol/mol [6.9%]). Sensor accuracy (39.3%), glycaemic performance (37.6%) and patch pump without tubing (27.5%) were the most commonly prioritised factors when selecting sensors, algorithms and insulin pumps, respectively. Treatment satisfaction priorities differed by age (p = 0.006), with younger participants more frequently prioritising reduction in burden and quality of life (QoL), whereas older participants prioritised hypoglycaemia-related outcomes. Although 63.8% perceived time in tight range (TITR, 3.9-7.8 mmol/L) ≥ 50% as beneficial for their health, only 36.1% considered it an achievable target. Most participants reported that closed-loop therapy improved QoL (78.6%), reduced hyperglycaemia (75.0%) and hypoglycaemia (72.3%), and met expectations (81.1%). Adequate support during closed-loop initiation was associated with therapy meeting participants' expectations (OR 16.6, 95% CI 5.0-52.4, p < 0.001).
Conclusions:
Adults with T1D reported diverse priorities and experiences relating to closed-loop therapy, extending beyond glycaemic outcomes alone. Adequate support during closed-loop initiation may represent an important component of successful implementation in routine clinical care.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Diabetes: Symptoms, Diagnosis, and Complications
Hyperglycemia
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...